Progress in functional genomics approaches to antifungal drug target discovery.
Antifungal drug discovery is starting to benefit from the enormous advances in the genomics field, which have occurred in the past decade. As traditional drug screening on existing targets is not delivering the long-awaited potent antifungals, efforts to use novel genetics and genomics-based strategies to aid in the discovery of novel drug targets are gaining increased importance. The current paradigm in antifungal drug target discovery focuses on basically two main classes of targets to evaluate: genes essential for viability and virulence or pathogenicity factors. Here we report on recent advances in genetics and genomics-based technologies that will allow us not only to identify and validate novel fungal drug targets, but hopefully in the longer run also to discover potent novel therapeutic agents. Fungal pathogens have typically presented significant obstacles when subjected to genetics, but the creativity of scientists in the anti-infectives field and the cross-talk with scientists in other areas is now yielding exciting new tools and technologies to tackle the problem of finding potent, specific and non-toxic antifungal therapeutics.
De Backer
Marianne D
MD
Johnson & Johnson Pharmaceuticals Group, Licensing and New Business Development, Technology Licensing, Turnhoutseweg 30, B-2340, Beerse, Belgium. mdbacker@janbe.jnj.com
Van Dijck
Patrick
P
D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D005658:Fungi / Q000187:drug effects; D020869:Gene Expression Profiling / Q000379:methods; D016681:Genome, Fungal; D023281:Genomics / Q000639:trends*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods
D000935:Antifungal Agents